← Browse by Condition
Medical Condition

ovarian cancer

Total Trials
56
Recruiting Now
56
Trial Phases
Phase 1, Phase 1, Phase 2, Phase 2

Ovarian cancer trials are shaped by the central role of BRCA1/2 mutation status and homologous recombination deficiency (HRD) in predicting response to PARP inhibitors β€” now standard maintenance therapy after first-line platinum-based chemotherapy for BRCA-mutated and HRD-positive disease. Despite PARP inhibitor approvals, platinum-resistant and BRCA wild-type advanced ovarian cancer remains a major unmet need driving frontline clinical research.

Active research includes next-generation PARP inhibitor combinations with anti-angiogenic agents and immune checkpoint inhibitors, mirvetuximab soravtansine (ADC targeting folate receptor alpha) in platinum-resistant disease, niraparib dose optimization, and VEGF/angiopoietin bispecific antibodies. Trials also evaluate intraperitoneal and heated intraperitoneal approaches for recurrent disease.

Most ovarian cancer trials require germline BRCA testing and often somatic tumor HRD testing; prior platinum therapy and number of prior lines determine eligibility for many studies.

Frequently Asked Questions — ovarian cancer Clinical Trials

How many clinical trials are currently recruiting for ovarian cancer?
ClinicalMetric currently tracks 56 actively recruiting clinical trials for ovarian cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 56. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for ovarian cancer?
ovarian cancer research spans Phase 1 (21 trials), Phase 2 (18 trials), Phase 3 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a ovarian cancer clinical trial?
Eligibility criteria for ovarian cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
21
Phase 2
18
Phase 3
4
Top Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 3 trials
University of California, Irvine 2 trials
University Health Network, Toronto 2 trials
Fudan University 2 trials
Women's Hospital School Of Medicine Zhejiang University 1 trial

Recruiting Clinical Trials

NCT06019923
Recruiting
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
Enrollment
100 pts
Location
China
Sponsor
Women's Hospital School Of Med...
View Trial →
NCT07125209
Recruiting
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
Enrollment
18 pts
Location
United States
Sponsor
University of Wisconsin, Madis...
View Trial →
NCT06307249 Phase 1
Recruiting
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Enrollment
50 pts
Location
Lebanon
Sponsor
Lebanese University
View Trial →
NCT07371104 Phase 1
Recruiting
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Enrollment
40 pts
Location
South Korea
Sponsor
Daewoong Pharmaceutical Co. LT...
View Trial →
NCT00722228 Phase 1, Phase 2
Recruiting
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Enrollment
50 pts
Location
Israel
Sponsor
Hadassah Medical Organization
View Trial →
NCT02754115
Recruiting
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Enrollment
400 pts
Location
India
Sponsor
Tata Memorial Centre
View Trial →
NCT05460000 Phase 2
Recruiting
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Enrollment
640 pts
Location
Austria, Belgium, Cz...
Sponsor
North Eastern German Society o...
View Trial →
NCT07610798 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Enrollment
178 pts
Location
China
Sponsor
Shenzhen Ionova Life Sciences ...
View Trial →
NCT05009082 Phase 3
Recruiting
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Enrollment
970 pts
Location
Germany
Sponsor
AGO Study Group
View Trial →
NCT04751435
Recruiting
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Enrollment
445 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT06873555 Phase 1, Phase 2
Recruiting
A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Heronova Pharmaceuticals
View Trial →
NCT06284343
Recruiting
The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Enrollment
1,800 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT05349227
Recruiting
Comprehensive Outcomes for After Cancer Health
Enrollment
625 pts
Location
United States
Sponsor
Pack Health
View Trial →
NCT07572409
Recruiting
Application of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study
Enrollment
52 pts
Location
China
Sponsor
manxiaxia
View Trial →
NCT06394492 Phase 3
Recruiting
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Enrollment
440 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT06395519 Phase 1, Phase 2
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Enrollment
120 pts
Location
United States
Sponsor
858 Therapeutics, Inc.
View Trial →
NCT07069335 Phase 1
Recruiting
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Enrollment
24 pts
Location
South Korea
Sponsor
Boryung Pharmaceutical Co., Lt...
View Trial →
NCT01441089
Recruiting
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Enrollment
1,100 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05645510
Recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Enrollment
75 pts
Location
Canada
Sponsor
University of Alberta
View Trial →
NCT06543537
Recruiting
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Enrollment
112 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT04503265 Phase 1, Phase 2
Recruiting
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Enrollment
122 pts
Location
United States
Sponsor
AtlasMedx, Incorporated
View Trial →
NCT06504147 Phase 2
Recruiting
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Enrollment
114 pts
Location
United States, Belgi...
Sponsor
Oncoinvent Solutions AS
View Trial →
NCT06366490 Phase 1
Recruiting
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Enrollment
8 pts
Location
United States
Sponsor
PhotonPharma, Inc.
View Trial →
NCT06182917
Recruiting
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
Enrollment
35 pts
Location
China
Sponsor
West China Second University H...
View Trial →
NCT07447050 Phase 2
Recruiting
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Enrollment
24 pts
Location
United States
Sponsor
University of California, Irvi...
View Trial →
NCT05810701
Recruiting
FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer
Enrollment
300 pts
Location
Denmark
Sponsor
Odense University Hospital
View Trial →
NCT04701645 Phase 1
Recruiting
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Enrollment
20 pts
Location
United States
Sponsor
Brigham and Women's Hospital
View Trial →
NCT06232122
Recruiting
Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
Enrollment
45 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
View Trial →
NCT06906341 Phase 2
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Enrollment
270 pts
Location
United States, Belgi...
Sponsor
Corcept Therapeutics
View Trial →
NCT06298877
Recruiting
Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer
Enrollment
450 pts
Location
Sweden
Sponsor
Sahar Salehi
View Trial →
NCT06473766
Recruiting
Ultrasound RF Data for Discriminating Between Benign and Malignant Ovarian Masses
Enrollment
50 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT06586957 Phase 1
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Enrollment
150 pts
Location
United States
Sponsor
NiKang Therapeutics, Inc.
View Trial →
NCT06689605
Recruiting
Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.
Enrollment
30 pts
Location
Czechia
Sponsor
University Hospital Hradec Kra...
View Trial →
NCT05952453 Phase 2
Recruiting
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
Enrollment
20 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT06907771
Recruiting
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
Enrollment
130 pts
Location
France
Sponsor
University Hospital, Strasbour...
View Trial →
NCT04590326 Phase 1, Phase 2
Recruiting
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Enrollment
612 pts
Location
United States, Belgi...
Sponsor
Regeneron Pharmaceuticals
View Trial →
NCT03917043 Phase 1
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
Enrollment
165 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
View Trial →
NCT06103916
Recruiting
Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice
Enrollment
613 pts
Location
Netherlands
Sponsor
Maxima Medical Center
View Trial →
NCT03287271 Phase 1, Phase 2
Recruiting
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
Enrollment
90 pts
Location
United States
Sponsor
Michael McHale
View Trial →
NCT05211557 Phase 1, Phase 2
Recruiting
Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer
Enrollment
15 pts
Location
China
Sponsor
The Affiliated Hospital of Xuz...
View Trial →
NCT02732860
Recruiting
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Enrollment
120 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT06476184 Phase 3
Recruiting
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Enrollment
250 pts
Location
France, Italy, Japan
Sponsor
ARCAGY/ GINECO GROUP
View Trial →
NCT03702309
Recruiting
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Enrollment
2,500 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT06999187 Phase 1
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Enrollment
96 pts
Location
United States
Sponsor
Dren Bio
View Trial →
NCT06249308
Recruiting
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
Enrollment
168 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06792435 Phase 1, Phase 2
Recruiting
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Enrollment
240 pts
Location
China
Sponsor
Evopoint Biosciences Inc.
View Trial →
NCT03452774
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Enrollment
50,000 pts
Location
United States, Puert...
Sponsor
Massive Bio, Inc.
View Trial →
NCT04520074 Phase 3
Recruiting
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Enrollment
590 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06735326 Phase 2
Recruiting
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Enrollment
105 pts
Location
China
Sponsor
Qilu Hospital of Shandong Univ...
View Trial →
NCT07023484 Phase 2
Recruiting
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Enrollment
126 pts
Location
China, Hong Kong
Sponsor
The University of Hong Kong
View Trial →
NCT07444814 Phase 1
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Enrollment
226 pts
Location
United States
Sponsor
Whitehawk Therapeutics, Inc.
View Trial →
NCT07064018 Phase 1, Phase 2
Recruiting
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
Enrollment
67 pts
Location
United States
Sponsor
University of California, Irvi...
View Trial →
NCT06392997
Recruiting
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
Enrollment
2,500 pts
Location
France
Sponsor
ZIWIG
View Trial →
NCT06085404
Recruiting
Patients Derived Organoids in Ovarian Cancer
Enrollment
48 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT05123482 Phase 1, Phase 2
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Enrollment
460 pts
Location
United States, Austr...
Sponsor
AstraZeneca
View Trial →
NCT07181720 Phase 1
Recruiting
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Enrollment
90 pts
Location
China
Sponsor
Chongqing Precision Biotech Co...
View Trial →

Related Conditions

breast cancer (13) endometrial cancer (10) colorectal cancer (8) lung cancer (8) fallopian tube cancer (7) cancer (5) gastric cancer (5) prostate cancer (5) melanoma (4) non small cell lung cancer (4) cervical cancer (4) peritoneal cancer (3)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology